keyword
MENU ▼
Read by QxMD icon Read
search

zoledronic

keyword
https://www.readbyqxmd.com/read/28339664/adult-paget-s-disease-of-bone-a-review
#1
Stephen Paul Tuck, Robert Layfield, Julie Walker, Babitha Mekkayil, Roger Francis
Adult PD of bone is the second commonest metabolic bone condition after osteoporosis. The condition is characterized by increased bone cell activity, with bone-resorbing osteoclasts often larger and containing more nuclei than normal, and osteoblasts producing increased amounts of disorganized bone. This leads to expanded bone of poor quality possessing both sclerotic and lytic areas. PD of bone has a strong genetic element, with a family history being noted in 10-20% of cases. A number of genetic defects have been found to be associated with the condition...
February 17, 2017: Rheumatology
https://www.readbyqxmd.com/read/28326300/the-efficacy-of-bisphosphonates-for-prevention-of-osteoporotic-fracture-an-update-meta-analysis
#2
Ji-Hye Byun, Sunmee Jang, Sumin Lee, Suyeon Park, Hyun Koo Yoon, Byung-Ho Yoon, Yong-Chan Ha
BACKGROUND: The efficacy of bisphosphonates for osteoporotic fracture has been consistently reported in recent randomized controlled trials (RCTs) enrolling hundreds of patients. The objective of this study was to update knowledge on the efficacy of available bisphosphonates in the prevention of vertebral and non-vertebral fractures. METHODS: An approach "using systematic reviews" on PubMed and Cochrane Library was taken. Twenty-four RCTs investigating the effects of bisphosphonates for the prevention of osteoporotic fracture were included in final analysis...
February 2017: Journal of Bone Metabolism
https://www.readbyqxmd.com/read/28324132/erratum-to-cost-effectiveness-analysis-of-once-yearly-injection-of-zoledronic-acid-for-the-treatment-of-osteoporosis-in-japan
#3
K Moriwaki, M Mouri, H Hagino
No abstract text is available yet for this article.
March 21, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28324123/long-term-bone-scintigraphy-results-after-intravenous-zoledronate-in-paget-s-disease-of-bone
#4
Ian R Reid, Katherine Maslowski
Zoledronate produces long-term normalization of biochemical markers in Paget's disease but whether this implies the absence of active disease is unknown. We have determined whether bone scintigraphy, a more sensitive index of disease activity, is also normalized ≥5 years after treatment with zoledronate. A consecutive case series of 11 individuals with Paget's disease treated with zoledronate 5 mg ≥5 years previously is reported. Eight patients received a single zoledronate infusion and were assessed 55-120 months later...
March 21, 2017: Calcified Tissue International
https://www.readbyqxmd.com/read/28323342/inflammatory-markers-and-frailty-in-long-term-care-residents
#5
Gabrielle A Langmann, Subashan Perera, Mary A Ferchak, David A Nace, Neil M Resnick, Susan L Greenspan
OBJECTIVES: To determine whether proinflammatory biomarkers are associated with frailty assessed according to functional status, mobility, mental health, and falls over 24 months. DESIGN: Secondary analysis of a 2-year double-blind clinical trial for osteoporosis. SETTING: Nursing homes and assisted living facilities. PARTICIPANTS: Women aged 65 and older with osteoporosis in long-term care (LTC) (N = 178). MEASUREMENTS: Baseline serum concentrations of proinflammatory cytokines and soluble receptors (high sensitivity C-reactive protein (hs-CRP), tumor necrosis factor alpha (TNFα) and its two receptors (TNFα-R1 and TNFα-R2), interleukin-6 (IL-6), soluble IL-6 receptor (sIL-6R), IL-10), functional status assessed according to activities of daily living, the Nursing Home Physical Performance Test, gait speed, cognitive status, mental health, and falls...
March 21, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/28323142/zoledronic-acid-improves-bone-histomorphometry-in-a-murine-model-of-rett-syndrome
#6
Jay R Shapiro, Adele L Boskey, Stephen B Doty, Lyudmila Lukashova, Mary E Blue
Rett syndrome (RTT) is a neurodevelopmental disorder predominately affecting young females, caused by deficiency of the global transcriptional protein methyl CpG binding protein 2 (MeCP2). Osteoblasts express MeCP2 and girls with RTT experience early onset osteoporosis, decreased bone mass and an increased fracture risk. There is no defined treatment for osteoporosis associated with RTT. The present study evaluated the effects of zoledronic acid (ZA), a third generation nitrogen-containing bisphosphonate with primarily anti-osteoclastic activity, in a mouse model of MeCP2 deficiency...
March 18, 2017: Bone
https://www.readbyqxmd.com/read/28318924/aged-rats-under-zoledronic-acid-therapy-and-oral-surgery
#7
Mariza Akemi Matsumoto, Elisa Mara de Abreu Furquim, Alaíde Gonçalves, Joel Ferreira Santiago-Júnior, Patrícia Pinto Saraiva, Camila Lopes Cardoso, Marcelo Salles Munerato, Roberta Okamoto
INTRODUCTION: Aging brings a number of health conditions that can compromise the healing process in elderly individuals, significantly when it comes to bone tissue. The aim of the present study was to analyze the effects of zoledronic acid (ZL) therapy on socket healing of aged male rats. MATERIALS AND METHODS: Twenty-four Wistar male rats, 20 months old, underwent surgical procedures for the extraction of the upper right incisor and were divided into two groups according to the treatment: Control (C) - intravenous (IV) 0...
February 17, 2017: Journal of Cranio-maxillo-facial Surgery
https://www.readbyqxmd.com/read/28300835/geranylgeranyl-diphosphate-synthase-inhibition-induces-apoptosis-that-is-dependent-upon-ggpp-depletion-erk-phosphorylation-and-caspase-activation
#8
Sherry S Agabiti, Jin Li, Andrew J Wiemer
Bisphosphonates are diphosphate analogs that inhibit the intermediate enzymes of the mevalonate pathway. Here, we compared the effects of a farnesyl diphosphate synthase inhibitor, zoledronate, and a geranylgeranyl diphosphate synthase (GGDPS) inhibitor, digeranyl bisphosphonate (DGBP), on lymphocytic leukemia cell proliferation and apoptosis. Both zoledronate and DGBP inhibited proliferation with DGBP doing so more potently. DGBP was markedly less toxic than zoledronate toward the viability of healthy human peripheral blood mononuclear cells...
March 16, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28300506/adding-celecoxib-with-or-without-zoledronic-acid-for-hormone-na%C3%A3-ve-prostate-cancer-long-term-survival-results-from-an-adaptive-multiarm-multistage-platform-randomized-controlled-trial
#9
Malcolm D Mason, Noel W Clarke, Nicholas D James, David P Dearnaley, Melissa R Spears, Alastair W S Ritchie, Gerhardt Attard, William Cross, Rob J Jones, Christopher C Parker, J Martin Russell, George N Thalmann, Francesca Schiavone, Estelle Cassoly, David Matheson, Robin Millman, Cyrill A Rentsch, Jim Barber, Clare Gilson, Azman Ibrahim, John Logue, Anna Lydon, Ashok D Nikapota, Joe M O'Sullivan, Emilio Porfiri, Andrew Protheroe, Narayanan Nair Srihari, David Tsang, John Wagstaff, Jan Wallace, Catherine Walmsley, Mahesh K B Parmar, Matthew R Sydes
Purpose Systemic Therapy for Advanced or Metastatic Prostate Cancer: Evaluation of Drug Efficacy is a randomized controlled trial using a multiarm, multistage, platform design. It recruits men with high-risk, locally advanced or metastatic prostate cancer who were initiating long-term hormone therapy. We report survival data for two celecoxib (Cel)-containing comparisons, which stopped accrual early at interim analysis on the basis of failure-free survival. Patients and Methods Standard of care (SOC) was hormone therapy continuously (metastatic) or for ≥ 2 years (nonmetastatic); prostate (± pelvic node) radiotherapy was encouraged for men without metastases...
March 13, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28299378/factors-associated-with-acute-phase-response-of-bisphosphonate-na%C3%A3-ve-or-pretreated-women-with-osteoporosis-receiving-an-intravenous-first-dose-of-zoledronate-or-ibandronate
#10
A W Popp, R Senn, I Curkovic, C Senn, H Buffat, P F Popp, K Lippuner
A first intravenous dose of bisphosphonates may be associated with an acute-phase response (APR). In bisphosphonate-naïve women with postmenopausal osteoporosis, the characteristics and frequency of APR may differ by compound. Prior bisphosphonate exposure was predictive of APR risk and severity. INTRODUCTION: Intravenous (IV) administration of bisphosphonates (BP), such as zoledronate (ZOL) and ibandronate (IBN), may be associated with an APR. The characteristics of APR may differ by compound...
March 15, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28296781/efficacy-and-safety-of-medical-therapy-for-low-bone-mineral-density-in-patients-with-crohn-disease-a-systematic-review-with-network-meta-analysis
#11
Xiaojing Zhao, Changcheng Zhou, Han Chen, Jingjing Ma, Yunjuan Zhu, Peixue Wang, Yi Zhang, Haiqin Ma, Hongjie Zhang
BACKGROUND: Low bone mineral density (BMD) is a frequent complication of inflammatory bowel disease (IBD), particularly in patients with Crohn disease (CD). The aim of our study is to determine the efficacy and safety of different drugs used to treat low BMD in patients with CD. METHODS: PUBMED/MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials were searched for eligible studies. A random-effects model within a Bayesian framework was applied to compare treatment effects as standardized mean difference (SMD) with their corresponding 95% credible interval (CrI), while odds ratio (OR) was applied to compare adverse events with 95% CrI...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28289967/a-pilot-trial-evaluating-zoledronic-acid-induced-changes-in-18-f-fmau-positron-emission-tomography-imaging-of-bone-metastases-in-prostate-cancer
#12
Ulka N Vaishampayan, Omid S Tehrani, Jawana M Lawhorn-Crews, Lance K Heilbrun, Kimberlee Dobson, Daryn Smith, Brenda Dickow, Anthony F Shields
PURPOSE: We conducted a pilot trial utilizing [(18)F]FMAU [1-(2'-deoxy-2'-[(18)F]fluoro-β-D-arabinofuranosyl thymine] as a tumor tracer in positron emission tomography (PET) and evaluated its reproducibility, and changes in maximum and peak standardized uptake value (SUVmax and SUVpeak) with zoledronic acid treatment in castrate resistant prostate cancer (CRPC) patients with bone metastases (BM). PROCEDURES: Eligible patients had CRPC with radiographic evidence of BM and creatinine clearance >30 ml/min...
March 13, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28287351/zoledronic-acid-treatment-in-primary-bone-marrow-edema-syndrome
#13
Bryan Josué Flores-Robles, Jesus Sanz-Sanz, Adel Abel Sanabria-Sanchinel, Dixie Huntley-Pascual, José Luis Andréu Sánchez, José Campos Esteban, Ricardo Blanco, Carolina Merino-Argumanez, Maria Espinosa-Malpartida, Maria Consuleo Ramos-Giráldez, Hildegarde Godoy-Tundidor, Maria Mercedes Jiménez-Palop, Carmen Barbadillo Mateos, Luis Fernando Villa-Alcázar, Carlos Maria Isasi, Juan Bartolome Mulero
Primary bone marrow edema syndrome (BMES) is characterized by the combination of joint pain and distinctive magnetic resonance imaging changes. It has been suggested that the use of bisphosphonate drugs reduce symptom severity. Our objective was to review cases of patients diagnosed with BMES in the last 7 years who had been treated with zoledronic acid. Access to a pharmaceutical database was gained in order to obtain a list of zoledronic acid prescriptions. Based on clinical and MRI criteria for BMES, patients were selected...
March 2017: Journal of Pain & Palliative Care Pharmacotherapy
https://www.readbyqxmd.com/read/28286299/importance-of-prompt-antiresorptive-therapy-in-postmenopausal-women-discontinuing-teriparatide-or-denosumab-the-denosumab-and-teriparatide-follow-up-study-data-follow-up
#14
Benjamin Z Leder, Joy N Tsai, Linda A Jiang, Hang Lee
When teriparatide and denosumab are discontinued, bone mineral density (BMD) abruptly decreases. To compare rates of bone loss in postmenopausal women who discontinue denosumab or teriparatide and receive no additional prescription osteoporosis medications to women who discontinue these drugs followed by prompt antiresorptive therapy, we asked women concluding the Denosumab and Teriparatide Administration (DATA) study and its extension, DATA-Switch, to return for BMD measurements 1-2years after study completion...
March 9, 2017: Bone
https://www.readbyqxmd.com/read/28284745/prolonged-use-of-zoledronic-acid-4-years-did-not-improve-outcome-in-multiple-myeloma-patients
#15
Agustin Avilès, Maria-Jesùs Nambo, Judith Huerta-Guzmàn, Sergio Cleto, Natividad Neri
BACKGROUND: Bisphosphonates, especially zoledronic acid (ZA), show antitumor effects in multiple myeloma (MM) and other neoplasms. The standard time for ZA administration has been 2 years. However, with improvement in overall survival (OS) in MM with new agents, it unclear whether ZA could be administered for a prolonged time to improve OS. PATIENTS AND METHODS: A total of 170 patients with untreated, symptomatic MM were randomly divided into a group to receive ZA for 4 years, with a control group to receive ZA for 2 years...
February 16, 2017: Clinical Lymphoma, Myeloma & Leukemia
https://www.readbyqxmd.com/read/28281643/reactive-oxygen-species-are-required-for-zoledronic-acid-induced-apoptosis-in-osteoclast-precursors-and-mature-osteoclast-like-cells
#16
Ta-Wei Tai, Ching-Yu Chen, Fong-Chin Su, Yuan-Kun Tu, Tsung-Ting Tsai, Chiou-Feng Lin, I-Ming Jou
Inhibiting osteoclasts and osteoclast precursors to reduce bone resorption is an important strategy to treat osteoclast-related diseases, such as osteoporosis, inflammatory bone loss, and malignant bone metastasis. However, the mechanism by which apoptosis is induced in the osteoclasts and their precursors are not completely understood. Here, we used nitrogen-containing bisphosphonate zoledronic acid (ZA) to induce cell apoptosis in human and murine osteoclast precursors and mature osteoclast-like cells. Caspase-3-mediated cell apoptosis occurred following the ZA (100 μM) treatment...
March 10, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28276638/intravenous-zoledronic-acid-5%C3%A2-mg-on-bone-turnover-markers-and-bone-mineral-density-in-east-china-subjects-with-newly-diagnosed-osteoporosis-a-24-month-clinical-study
#17
Bo-Cheng Liang, Zhen-Yu Shi, Bo Wang, Peng Wu, Ling-Cheng Kong, Jian-Liang Yao, Chun-Wen Li, Xiao-Lin Shi
OBJECTIVE: This randomized, double-blind, placebo-controlled study assessed the necessity of early intervention, safety and efficacy of intravenous zoledronic acid 5 mg/year in East China women with newly diagnosed osteoporosis at high risk of fracture during a 24-month treatment period. METHODS: Subjects (57 [52-62] years old) were randomized 3:2 to zoledronic acid versus placebo (randomized at baseline, zoledronic acid [175 cases], placebo-zoledronic acid [110 cases])...
March 9, 2017: Orthopaedic Surgery
https://www.readbyqxmd.com/read/28270269/retained-skeletal-effects-of-zoledronic-acid-following-discontinuation-of-treatment-a-review-of-the-literature
#18
Crystal M Deas, Pilar Murphy, Maryam Iranikhah, Maisha Kelly Freeman
OBJECTIVE: To evaluate the effects on bone mineral density (BMD), bone turnover markers (BTMs), and fracture incidence following zoledronic acid (ZOL) discontinuation. DATA SOURCES: A search of PubMed (1966-May 2016) and International Pharmaceutical Abstracts (1970-May 2016) was conducted using the MeSH terms zoledronic acid, osteoporosis, and withholding treatment. Free text searches included drug holiday and drug discontinuation. STUDY SELECTION AND DATA EXTRACTION: An initial review yielded 87 articles...
March 1, 2017: Consultant Pharmacist: the Journal of the American Society of Consultant Pharmacists
https://www.readbyqxmd.com/read/28265718/cost-effectiveness-analysis-of-once-yearly-injection-of-zoledronic-acid-for-the-treatment-of-osteoporosis-in-japan
#19
K Moriwaki, M Mouri, H Hagino
Model-based economic evaluation was performed to assess the cost-effectiveness of zoledronic acid. Although zoledronic acid was dominated by alendronate, the incremental quality-adjusted life year (QALY) was quite small in extent. Considering the advantage of once-yearly injection of zoledronic acid in persistence, zoledronic acid might be a cost-effective treatment option compared to once-weekly oral alendronate. INTRODUCTION: The purpose of this study was to estimate the cost-effectiveness of once-yearly injection of zoledronic acid for the treatment of osteoporosis in Japan...
March 6, 2017: Osteoporosis International
https://www.readbyqxmd.com/read/28264701/zoledronic-acid-alters-hematopoiesis-and-generates-breast-tumor-suppressive-bone-marrow-cells
#20
Jessalyn M Ubellacker, Marie-Therese Haider, Molly J DeCristo, Gloria Allocca, Nicola J Brown, Daniel P Silver, Ingunn Holen, Sandra S McAllister
BACKGROUND: The bone-targeting agent zoledronic acid (ZOL) increases breast cancer survival in subsets of patients, but the underlying reasons for this protective effect are unknown. ZOL modulates the activity of osteoclasts and osteoblasts, which form hematopoietic stem cell niches, and therefore may affect hematopoietic cells that play a role in breast cancer progression. METHOD: Immunocompetent and immunocompromised strains of mice commonly used for breast cancer research were injected with a single, clinically relevant dose of ZOL (100 μg/kg) or vehicle control...
March 6, 2017: Breast Cancer Research: BCR
keyword
keyword
113547
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"